Aug 19, 2016
Zymeworks licenses new drug discovery platform from Innovative Targeting Solutions Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG, which works as a protein engineering platform, and is the first fully mammalian tech that...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper